Business Context and Reporting Period
Kura Oncology, Inc. (KURA) filed a Form 8-K on August 1, 2019, to announce financial results for the second quarter ended June 30, 2019, and to provide a corporate update. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only indicates that such results were announced in the accompanying press release.
Guidance, Outlook, and Risks
The filing references a corporate update and financial results but does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items within the text provided. The information is explicitly noted as furnished and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 1, 2019) for specific Q2 2019 financial figures.
- Verify the company's cash runway and burn rate from the full press release.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the corporate update.
- Check for any new debt instruments or equity financing activities not detailed in this summary.